

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

**PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND
ARTICLES OF ASSOCIATION AND
ADOPTION OF THE NEW MEMORANDUM AND
ARTICLES OF ASSOCIATION**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to amend (the “**Proposed Amendments**”) the existing memorandum and articles of association of the Company (the “**Existing Memorandum and Articles of Association**”) in order to align with the latest regulatory requirements in relation to the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules which took effect from 31 December 2023 and incorporate certain housekeeping amendments. The Board also proposes to adopt the second amended and restated memorandum and articles of association of the Company (the “**New Memorandum and Articles of Association**”) which consolidates the Proposed Amendments in substitution for, and to the exclusion of, the Existing Memorandum and Articles of Association in their entirety.

The Proposed Amendments and the adoption of the New Memorandum and Articles of Association are subject to the approval of the shareholders of the Company by way of a special resolution at the extraordinary general meeting of the Company (the “**EGM**”) to be convened and held by the Company. A circular containing, inter alia, details of the Proposed Amendments and the adoption of the New Memorandum and Articles of Association, together with a notice convening the EGM, will be despatched to the shareholders of the Company in due course.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 28 March 2024

As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Xu Hanxing as executive Directors; Doctor Zhang Lihua as a non-executive Director; and Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive Directors.